Dose Insider / Glossary / Dulaglutide

DulaglutideWhat it is, how Trulicity is taken and what REWIND showed

Updated November 20, 2026 · 3 min read · TRULICITY prescribing information, DailyMed, August 2026

Dulaglutide is a GLP-1 receptor agonist injected once a week, sold by Eli Lilly as Trulicity and first approved in the United States in 2014.

12.0%Trulicity 1.5 mg, heart events in REWIND
Heart events in REWINDFirst heart attack, stroke or CV deathTrulicity 1.5 mg12.0%Placebo13.4%Heart events in REWINDFirst heart attack, stroke or CV deathTrulicity 1.5 mg12.0%Placebo13.4%

9,901 adults followed for a median of 5.4 years; hazard ratio 0.88.

On this page

With diet and exercise, it is approved to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes. It is also approved to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who have heart disease or several cardiovascular risk factors. It is not approved for weight loss.1

How the molecule is built

Dulaglutide takes a different route to a long half-life from semaglutide and liraglutide, which bind to albumin through a fatty acid. It is a fusion protein: two identical chains, each with a GLP-1 analog at one end joined by a short linker to the Fc portion of a modified human antibody, immunoglobulin G4. It is made in Chinese hamster ovary cell culture, and its GLP-1 part is 90% similar to human GLP-1, with changes that protect it from the enzyme DPP-4.1

The result is a half-life of about 5 days. At steady state the level peaks 24 to 72 hours after an injection, with a median of 48 hours.1 That is close to tirzepatide's half-life of about 5 days and shorter than semaglutide's of about 1 week.2,3

How the dose climbs

For adults Trulicity starts at 0.75 mg once a week. After 4 weeks it may go to 1.5 mg, and if more blood sugar control is needed it rises in steps of 1.5 mg, each after at least 4 weeks, to a maximum of 4.5 mg. For children aged 10 and older the maximum is 1.5 mg.1 Our page on timing a weekly GLP-1 shot covers changing the day and missed doses across the weekly medicines.

The REWIND heart trial

REWIND enrolled 9,901 adults with type 2 diabetes and either established cardiovascular disease or several cardiovascular risk factors, and followed them for a median of 5.4 years on Trulicity 1.5 mg or placebo, added to usual care.1

The labels describe LEADER and the Ozempic heart trial as trials in adults with atherosclerotic cardiovascular disease. REWIND also took people with risk factors alone, and the Trulicity heart indication covers both groups.1,2,4

Side effects and warnings

In the pooled placebo-controlled trials, nausea was reported by 12.4% on 0.75 mg and 21.1% on 1.5 mg, against 5.3% on placebo. Diarrhea was reported by 8.9% and 12.6% against 6.7%, and vomiting by 6.0% and 12.7% against 2.3%.1 In the trial of the higher doses, nausea was reported by 13.4% on 1.5 mg, 15.6% on 3 mg and 16.4% on 4.5 mg.1

Trulicity carries the boxed warning about thyroid C-cell tumors seen in rats and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1 Our page on nausea on a GLP-1 covers what helps.

Dulaglutide in eight lines

FactTrulicity
Active ingredientDulaglutide
MakerEli Lilly
First U.S. approval2014
How oftenOnce a week, under the skin
Doses0.75 mg to start, up to 4.5 mg
Half-lifeAbout 5 days
Built asGLP-1 analog fused to an antibody fragment
Approved for weight lossNo

TRULICITY prescribing information, DailyMed version of August 10, 2026.1

Liraglutide and semaglutide are the GLP-1 receptor agonists built on albumin binding; tirzepatide, from the same maker as dulaglutide, adds a second receptor. Our page on Ozempic and Mounjaro compares the two most used weekly diabetes injections.

Sources

  1. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, U.S. National Library of Medicine, version published August 10, 2026; boxed warning and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
  2. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 12.3 and 14.2. accessdata.fda.gov
  3. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 12.3. accessdata.fda.gov
  4. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published November 17, 2025; section 14. dailymed.nlm.nih.gov

Related analyses

Log each weekly dose and see your week, levels and symptoms together.

Open Dose Insider